Basal cell carcinoma study meets endpoints – Novartis

Novartis said that an experimental drug for advanced basal cell carcinoma, the most common form of skin cancer, met its primary endpoint in a Phase 2 study. The treatment, LDE225, is a molecule that regulates the hedgehog signaling pathway.